LGVN stock jumped on March 13, 2026 after Longeveron Inc. reported Q4 activity and closed a private placement that extended funding into late 2026. The share price moved to $0.97 on volume of 13,377,831 shares, up 20.33% for the day. Investors now focus on the company’s March 17, 2026 after-market earnings and how cash runway and the HLHS program will shape near-term valuation. We review financials, trading signals, and the company’s capital plan for the NASDAQ-listed biotechnology firm.
LGVN stock: market move and catalysts
Longeveron Inc. (LGVN) rose to $0.97 following news of a private placement and the scheduled March 17, 2026 earnings announcement. The company reported an initial tranche of approximately $15.00 million in gross proceeds and said proceeds should fund operations into 4Q26. The stock’s intraday range was $0.84–$1.10 with average volume 4,731,933 shares, and today’s volume of 13,377,831 shows elevated interest. The immediate catalyst remains the Q4 2025 results and management commentary after markets close on March 17.
Financials and valuation: key metrics for LGVN stock
Longeveron reports trailing EPS of -0.98 and a negative PE of -0.99, reflecting ongoing losses in this clinical-stage biotech. Market capitalization stands near $20,767,559.00 with 21,332,880 shares outstanding. Balance-sheet metrics include cash per share $0.50, book value per share $0.54, current ratio 2.09, and debt to equity 0.10. Price averages show a 50-day mean of $0.57 and a 200-day mean of $0.87, indicating the stock sits above its longer-term average but below its 52-week high of $1.92.
Meyka AI grades LGVN stock and valuation signals
Meyka AI rates LGVN with a score out of 100: 65.63 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating from aggregated models at the time is C with a sell tilt, but Meyka’s score balances that with progress on financing and trial milestones. These grades are model outputs and are not investment advice.
Technicals, momentum and trading signals for LGVN stock
Technical indicators show a strong short-term trend: RSI 69.29, ADX 33.83, and MACD histogram positive. Momentum metrics are extended with CCI 144.07 and MFI 97.18, signaling overbought conditions. The stock’s relative volume is 2.82, suggesting outsized intraday interest. Traders should note high volatility (ATR 0.10) and that both short-term mean reversion and event-driven swings are likely ahead of earnings.
Clinical progress, funding and risk factors impacting LGVN stock
Longeveron’s lead candidate, laromestrocel (LOMECEL-B®), targets aging frailty, Alzheimer’s disease, HLHS and pediatric DCM, and carries multiple FDA designations for select programs. The private placement provides runway into Q4 2026 and aligns financing with the pivotal Phase 2b ELPIS II HLHS readout planned for 3Q26. Key risks include trial readouts, potential dilution from additional financings, and the small market cap of $20.77M, which increases sensitivity to single announcements. See the company press release and financing details source and the private placement filing source.
Final Thoughts
Key takeaways for LGVN stock center on imminent earnings and recently secured financing. The company closed an initial $15.00 million tranche that should fund operations into 4Q26 and support clinical milestones including the 3Q26 HLHS readout. Trailing metrics show an EPS of -0.98, negative PE, and cash per share $0.50, leaving valuation tied to trial outcomes rather than revenue. Meyka AI’s forecast model projects $0.36, compared with the current price (USD 0.9735) and implies an approximate -63.00% downside if model assumptions hold. Price targets that reflect clinical binary risk could range from $0.30 (bear) to $1.50 (bull), with a base case near $0.90. Forecasts are model-based projections and not guarantees. Given the event-driven setup, investors should weigh clinical timelines, dilution risk, and sector peer moves before changing positions. Meyka AI, an AI-powered market analysis platform, provides these data-driven views to inform your research.
FAQs
When will Longeveron report earnings and how does it affect LGVN stock?
Longeveron will report 2025 results on March 17, 2026 after U.S. markets close. The earnings call and guidance will directly affect LGVN stock because the company is clinical-stage and price moves depend on cash runway and trial updates.
What is Meyka AI’s forecast for LGVN stock and the implied change?
Meyka AI’s forecast model projects $0.36 for LGVN stock, versus the current price (USD 0.9735), implying an approximate -63.00% downside. Forecasts are model-based projections and not guarantees.
What are the main risks investors should watch for in LGVN stock?
Primary risks are clinical trial outcomes, potential dilution from additional financings, and limited market-cap liquidity. LGVN stock is sensitive to single trial readouts and funding updates given the company’s clinical-stage profile.
How did the recent private placement affect LGVN stock outlook?
The private placement provided an initial $15.00 million tranche and extended runway into Q4 2026, reducing near-term financing pressure. The deal also links additional funding to HLHS milestones, which ties stock upside to trial progress.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)